Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia Arthur Gomes Oliveira Braga; Katia Borgia Barbosa Pagnano; Marina Dal'Bó Pelegrini Campioni; Ana Beatriz Pascoal Lopes; Gislaine Oliveira Duarte; Konradin Metze; Irene Lorand-Metze;

Overall survival in multiple myeloma in Brazil: A cohort of 16 years Deborah Marta do Santos Oliveira; Adriano de Paula Sabino; Francisco de Assis Acurcio; Isabella Zuppo; Juliana Alvares Teodoro; Pâmela Santos Azevedo; Isabela Cristina Menezes de Freitas; Wallace Mateus Prata; Marisa Yurico Itonaga; Carmino Antonio de Souza; Mariângela Leal Cherchiglia; Augusto Afonso Guerra Junior;

REVERSAL OF ACCELERATED PHASE CML WITH HIGH BLAST COUNT FOLLOWING 5+2 CHEMOTHERAPY AND DASATINIB: A CASE REPORT Bü¿ra Akdo¿an; Ali Turunç; Birol Güvenç;